ProQR Therapeutics NV reports results for the quarter ended June 30 - Earnings Summary

• ProQR Therapeutics NV PRQR reported a quarterly adjusted loss of 12 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -3 cents. The mean expectation of seven analysts for the quarter was for a loss of 8 cents per share. Wall Street expected results to range from -13 cents to -4 cents per share.

• Revenue fell 39.5% to €3.82 million from a year ago; analysts expected €4.45 million.

• ProQR Therapeutics NV's reported EPS for the quarter was a loss of 12 cents​.

• The company reported a quarterly loss of €12.18 million.

• ProQR Therapeutics NV shares had risen by 1.0% this quarter and lost 22.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 5.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for ProQR Therapeutics NV is $9.00, about 77.1% above its last closing price of $2.06

This summary was machine generated from LSEG data August 7 at 05:40 p.m. UTC. ​All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)